Please find enclosed Investor Presentation on Q4 & FY26 Results
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories reported Q4 FY26 revenue of Rs. 472 crore, up 22% YoY, with FY26 full-year revenue of Rs. 597 crore (up 8%). The company secured a major multi-year manufacturing mandate worth Rs. 823 crore, with commercial production now commenced. EBITDA margins contracted to 8.6% in FY26 from 10.8% in FY25 due to manufacturing scale-up investments, though PAT improved to 3.9% from 3.1%. Management targets EBITDA improvement from current ~10-11% range to 20%+ profile as long-duration programs ramp up and operating leverage kicks in. Capacity is expanding from ~500 KL to ~1,000 KL. Medical Devices division showed strong 31% Q4 growth. The company highlights its 4th consecutive USFDA inspection with NIL 483 observations.
Positive signal for shareholders as the company secured a large Rs. 823 crore multi-year order, commenced commercial production, and set a clear 20%+ EBITDA margin target. Near-term profitability remains pressured by investments but long-term visibility has improved significantly.